Brevan Howard Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Brevan Howard Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Buy	250,291 +82,320	+49%	+$1.14M	0.03%	456
2026 Q1	$2.46M	Buy	+167,971	New	+$2.68M	0.02%	476
2025 Q4	–	Sell	-15,300	Closed	-$113K	–	1890
2025 Q3	$113K	Buy	+15,300	New	+$78.3K	﹤0.01%	1854
2025 Q2	–	Sell	-21,738	Closed	-$69.1K	–	1868
2025 Q1	$69.1K	Buy	+21,738	New	+$102K	﹤0.01%	1074

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Brevan Howard Capital Management's CRVS Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 49% in Q2 2026, buying an estimated $1.14M and bringing the position to 250,291 shares worth $3.74M. The position accounts for 0.03% of the portfolio, ranked #456.

Brevan Howard Capital Management first reported a position in CRVS in Q1 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Brevan Howard Capital Management held 250,291 shares of Corvus Pharmaceuticals worth $3.74M as of Q2 2026.
Brevan Howard Capital Management bought 82,320 Corvus Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
Corvus Pharmaceuticals made up 0.03% of Brevan Howard Capital Management's portfolio in Q2 2026, its #456 holding.
Brevan Howard Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 4 quarters since.
173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.